Latest Sorafenib Stories
LONDON, Feb. 26, 2015 /PRNewswire/ -- Kidneys are among the most crucial organs of the human body.
Initiation of Registrational Studies Planned for This Year MORRISTOWN, N.J., Jan.
First-in-Class Agent is Well Tolerated in Liver Cancer Patients SAN ANTONIO, Jan.
Trial follows successful Phase I/II study which met all study endpoints PETACH TIKVA, Israel, Dec.
SAN DIEGO, Dec.
OTTAWA, Oct. 30, 2014 /CNW Telbec/ - Health Canada today released the October 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc.
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.